Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Pharmaceutical Group To Accelerate Business Integration

This article was originally published in PharmAsia News

Executive Summary

Beijing Pharmaceutical Group's commercial business is contributed by its five entities across China: Worldbest Pharmaceutical in Anhui, Beijing Pharmaceutical in Beijing, Double-crane Pharmaceutical in Kunshan, Xin-xibei Double-crane Medicine in Xi'an and Double-crane Medicine in Changsha. The group revealed that it plans to integrate its pharmaceutical business to maintain its market share in North China and achieve market penetration in areas such as Anhui, Hunan and Shaanxi. Analysts observe that China's pharmaceutical giants like Nanjing Medical Company, Guangzhou Pharmaceutical and Shanghai Pharmaceutical frequently formulate strategies to grab distribution channels and resources; their activities may have spurred Beijing Pharmaceutical Group's latest direction. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068173

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel